• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

ABIONYX Pharma formerly Cerenis Therapeutics

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

ABIONYX Pharma formerly Cerenis Therapeutics

Investment: 2006
Visit Website

ABIONYX Pharma is a new biotech company dedicated to the discovery and development of innovative therapies for
patients. The biotech assets from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of
cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery
platform in oncology, more specifically in immuno-oncology and chemotherapy, as well as molecules targeted for other
indications.

 

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact